Logo 1 Logo 2

Clinical Trial Details

Trial ID: L2768
Source ID: NCT00506662
Associated Drug: Insulin Detemir
Title: Comparison of Insulin Detemir and NPH Insulin Given Once Daily in Ageing Subjects With Type 2 Diabetes
Acronym: 3L
Status: TERMINATED
Study Results: YES
Results: https://ClinicalTrials.gov/show/NCT00506662/results
Conditions: Diabetes|Diabetes Mellitus, Type 2
Interventions: DRUG: insulin detemir|DRUG: insulin NPH
Outcome Measures: Primary: Change in Glycosylated Haemoglobin (HbA1c) at Month 7, week 0, month 7 | Secondary: Change in Glycosylated Haemoglobin (HbA1c) at Month 4, week 0, month 4|Change in Mean Fasting Plasma Glucose (FPG) at Month 7, week 0, month 7|Change in Mean Fasting Plasma Glucose (FPG) at Month 4, week 0, month 4|Change in Mean Pre-lunch Plasma Glucose at Month 7, week 0, month 7|Change in Mean Pre-lunch Plasma Glucose at Month 4, week 0, month 4|Change in Mean Pre-dinner Plasma Glucose at Month 7, week 0, month 7|Change in Mean Pre-dinner Plasma Glucose at Month 4, week 0, month 4|Change in Body Weight at Month 7, week 0, month 7|Change in Body Weight at Month 4, week 0, month 4|Mean Number of Total Hypoglycaemic Episodes, Month 1, Mean number of total hypoglycaemic episodes per patient expressed as rate per week by visit. Rate per week is calculated by dividing the number of episodes for each patient by the number of weeks in the period., weeks -2-0, month 1|Mean Number of Total Hypoglycaemic Episodes, Months 2-4, Mean number of total hypoglycaemic episodes per patient expressed as rate per week by visit. Rate per week is calculated by dividing the number of episodes for each patient by the number of weeks in the period., weeks -2-0, months 2-4|Mean Number of Total Hypoglycaemic Episodes, Months 5-7, Mean number of total hypoglycaemic episodes per patient expressed as rate per week by visit. Rate per week is calculated by dividing the number of episodes for each patient by the number of weeks in the period., weeks -2-0, months 5-7
Sponsor/Collaborators: Sponsor: Novo Nordisk A/S
Gender: ALL
Age: OLDER_ADULT
Phases: PHASE4
Enrollment: 86
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2007-07
Completion Date: 2008-12
Results First Posted: 2010-11-17
Last Update Posted: 2023-08-14
Locations: Paris La Défense, 92936, France|Cambridge, CB2 2QQ, United Kingdom
URL: https://clinicaltrials.gov/show/NCT00506662